Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use

References

• Neunert C, Terrell DR, Arnold DM, et al. American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi:10.1182/bloodadvances.2019000966
   PubMed Web of Science ®Google Scholar
• Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6(2):16. doi:10.3390/jcm6020016
   PubMed Web of Science ®Google Scholar
• Yazdanbakhsh K. Imbalanced immune homeostasis in immune thrombocytopenia. Semin Hematol. 2016;53(Suppl 1):S16–S19. doi:10.1053/j.seminhematol.2016.04.006
   PubMedGoogle Scholar
• Olsson B, Andersson PO, Jernas M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123–1124. doi:10.1038/nm921
   PubMed Web of Science ®Google Scholar
• Liu B, Zhao H, Poon MC, et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007;78(2):139–143. doi:10.1111/j.1600-0609.2006.00780.x
   PubMed Web of Science ®Google Scholar
• Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103(2):500–506. doi:10.1182/blood-2003-01-0275
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:10.1182/blood-2008-07-162503
   PubMed Web of Science ®Google Scholar
• Kuhne T, Berchtold W, Michaels LA, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the intercontinental cooperative immune thrombocytopenia study group. Haematologica. 2011;96(12):1831–1837. doi:10.3324/haematol.2011.050799
   PubMed Web of Science ®Google Scholar
• Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457–464. doi:10.1111/jth.12813
   PubMed Web of Science ®Google Scholar
• Heitink-Polle KMJ, Uiterwaal C, Porcelijn L, et al. Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial. Blood. 2018;132(9):883–891. doi:10.1182/blood-2018-02-830844
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207. doi:10.1182/blood-2010-08-302984
   PubMed Web of Science ®Google Scholar
• Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Northern Region Haematology G. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122(6):966–974. doi:10.1046/j.1365-2141.2003.04547.x
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9):2549–2554. doi:10.1182/blood.V97.9.2549
   PubMed Web of Science ®Google Scholar
• Schifferli A, Holbro A, Chitlur M, et al. A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up. Am J Hematol. 2018;93(6):751–759. doi:10.1002/ajh.25086
   PubMed Web of Science ®Google Scholar
• Ahmed R, Devasia AJ, Viswabandya A, et al. Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children: splenectomy in ITP. Ann Hematol. 2016;95(9):1429–1434. doi:10.1007/s00277-016-2738-3
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Arista MC, Peraino M, et al. Long-term follow-up of autoimmune thrombocytopenic purpura (ATP) patients submitted to splenectomy. Eur J Haematol. 1999;62(4):219–222. doi:10.1111/j.1600-0609.1999.tb01750.x
   Web of Science ®Google Scholar
• Ejstrud P, Kristensen B, Hansen JB, Madsen KM, Schonheyder HC, Sorensen HT. Risk and patterns of bacteraemia after splenectomy: a population-based study. Scand J Infect Dis. 2000;32(5):521–525. doi:10.1080/003655400458811
   Google Scholar
• Theilacker C, Ludewig K, Serr A, et al. Overwhelming postsplenectomy infection: a prospective multicenter cohort study. Clin Infect Dis. 2016;62(7):871–878. doi:10.1093/cid/civ1195
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica. 2014;99(2):392–398. doi:10.3324/haematol.2013.092460
   PubMed Web of Science ®Google Scholar
• Linet MS, Nyren O, Gridley G, et al. Causes of death among patients surviving at least one year following splenectomy. Am J Surg. 1996;172(4):320–323. doi:10.1016/S0002-9610(96)00196-1
   Web of Science ®Google Scholar
• Mellemkjoer L, Olsen JH, Linet MS, Gridley G, McLaughlin JK. Cancer risk after splenectomy. Cancer. 1995;75(2):577–583. doi:10.1002/1097-0142(19950115)75:2<577::AID-CNCR2820750222>3.0.CO;2-K
   Web of Science ®Google Scholar
• Sun LM, Chen HJ, Jeng LB, Li TC, Wu SC, Kao CH. Splenectomy and increased subsequent cancer risk: a nationwide population-based cohort study. Am J Surg. 2015;210(2):243–251. doi:10.1016/j.amjsurg.2015.01.017
   Web of Science ®Google Scholar
• Robinette CD, Fraumeni JF Jr. Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet. 1977;2(8029):127–129. doi:10.1016/S0140-6736(77)90132-5
   PubMed Web of Science ®Google Scholar
• Grace RF, Shimano KA, Bhat R, et al. Second-line treatments in children with immune thrombocytopenia: effect on platelet count and patient-centered outcomes. Am J Hematol. 2019;94(7):741–750. doi:10.1002/ajh.25479
   PubMed Web of Science ®Google Scholar
• Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77(7):1117–1124. doi:10.1016/0092-8674(94)90450-2
   PubMed Web of Science ®Google Scholar
• de Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369(6481):533–538. doi:10.1038/369533a0
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994;91(23):11104–11108. doi:10.1073/pnas.91.23.11104
   PubMed Web of Science ®Google Scholar
• Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369(6481):565–568. doi:10.1038/369565a0
   PubMed Web of Science ®Google Scholar
• Foster DC, Sprecher CA, Grant FJ, et al. Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci U S A. 1994;91(26):13023–13027. doi:10.1073/pnas.91.26.13023
   PubMed Web of Science ®Google Scholar
• Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98(1):10–23. doi:10.1007/s12185-013-1382-0
   PubMed Web of Science ®Google Scholar
• Kim TO, Despotovic J, Lambert MP. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018;2(4):454–461. doi:10.1182/bloodadvances.2017010660
   PubMed Web of Science ®Google Scholar
• Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999;106(2):345–356. doi:10.1046/j.1365-2141.1999.01571.x
   PubMed Web of Science ®Google Scholar
• Grozovsky R, Giannini S, Falet H, Hoffmeister KM. Novel mechanisms of platelet clearance and thrombopoietin regulation. Curr Opin Hematol. 2015;22(5):445–451. doi:10.1097/MOH.0000000000000170
   Web of Science ®Google Scholar
• McIntosh B, Kaushansky K. Transcriptional regulation of bone marrow thrombopoietin by platelet proteins. Exp Hematol. 2008;36(7):799–806. doi:10.1016/j.exphem.2008.02.012
   Web of Science ®Google Scholar
• Kuter DJ, Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am. 2009;23(6):1193–1211. doi:10.1016/j.hoc.2009.09.001
   PubMed Web of Science ®Google Scholar
• Nichol JL, Endogenous TPO (eTPO) levels in health and disease: possible clues for therapeutic intervention. Stem Cells. 1998;16(Suppl 2):165–175. doi:10.1002/stem.5530160719
   PubMedGoogle Scholar
• Kuter DJ. Whatever happened to thrombopoietin? Transfusion. Mar. 2002;42(3):279–283.
   Google Scholar
• Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98(12):3241–3248. doi:10.1182/blood.V98.12.3241
   PubMed Web of Science ®Google Scholar
• Kong Z, Qin P, Xiao S, et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood. 2017;130(9):1097–1103. doi:10.1182/blood-2017-01-761262
   PubMed Web of Science ®Google Scholar
• Wang S, Yang R, Zou P, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 2012;96(2):222–228. doi:10.1007/s12185-012-1124-8
   PubMed Web of Science ®Google Scholar
• Molineux G. The development of romiplostim for patients with immune thrombocytopenia. Ann N Y Acad Sci. 2011;1222(1):55–63. doi:10.1111/j.1749-6632.2011.05975.x
   Google Scholar
• Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76(6):628–638. doi:10.1016/j.clpt.2004.08.010
   PubMed Web of Science ®Google Scholar
• Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2004;25(2):52–60. doi:10.1016/j.cyto.2003.05.001
   PubMed Web of Science ®Google Scholar
• Wang YM, Krzyzanski W, Doshi S, Xiao JJ, Perez-Ruixo JJ, Chow AT. Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 2010;12(4):729–740. doi:10.1208/s12248-010-9234-9
   PubMed Web of Science ®Google Scholar
• Romiplostim. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125268s164lbl.pdf. Accessed November 20, 2019.
   Google Scholar
• Newland A, Godeau B, Priego V, et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a Phase 2 study. Br J Haematol. 2016;172(2):262–273. doi:10.1111/bjh.13827
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403. doi:10.1016/S0140-6736(08)60203-2
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363(20):1889–1899. doi:10.1056/NEJMoa1002625
   PubMed Web of Science ®Google Scholar
• Neunert C, Despotovic J, Haley K, et al. Thrombopoietin receptor agonist use in children: data from the pediatric ITP consortium of north america ICON2 study. Pediatr Blood Cancer. 2016;63(8):1407–1413. doi:10.1002/pbc.26003
   PubMed Web of Science ®Google Scholar
• Cines DB, Wasser J, Rodeghiero F, et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Haematologica. 2017;102(8):1342–1351. doi:10.3324/haematol.2016.161968
   PubMed Web of Science ®Google Scholar
• Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion. 2013;53(11):2807–2812. doi:10.1111/trf.12139
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Giagounidis A, et al. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol. 2013;91(5):423–436. doi:10.1111/ejh.12181
   PubMedGoogle Scholar
• Cervinek L, Mayer J, Doubek M. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Int J Hematol. 2015;102(1):7–11. doi:10.1007/s12185-015-1793-1
   PubMed Web of Science ®Google Scholar
• Mahevas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165(6):865–869. doi:10.1111/bjh.12888
   PubMed Web of Science ®Google Scholar
• Rodeghiero F. Is ITP a thrombophilic disorder? Am J Hematol. Jan. 2016;91(1):39–45.
   Google Scholar
• Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45–54. doi:10.1016/S0140-6736(16)00279-8
   PubMed Web of Science ®Google Scholar
• Rizvi H, Butler T, Calaminici M, et al. United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings. Br J Haematol. 2015;169(4):590–594. doi:10.1111/bjh.13330
   PubMed Web of Science ®Google Scholar
• Lee JW, Lee SE, Jung CW, et al. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial. Lancet Haematol. 2019;6(11):e562–e572. doi:10.1016/S2352-3026(19)30153-X
   PubMed Web of Science ®Google Scholar
• Grace RF, Despotovic JM, Bennett CM, et al. Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. Am J Hematol. 2018;93(7):882–888. doi:10.1002/ajh.25110
   PubMed Web of Science ®Google Scholar
• Zhang J, Liang Y, Ai Y, et al. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. PLoS One. 2018;13(6):e0198504. doi:10.1371/journal.pone.0198504
   PubMed Web of Science ®Google Scholar
• Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479–490. doi:10.1111/bjh.15573
   PubMed Web of Science ®Google Scholar
• Lexicomp Online PaNL-DO, Hudson, Ohio: wolters Kluwer Clinical Drug Information, Inc. December. 2019;6:2019.
   Google Scholar
• Trotter P, Hill QA. Immune thrombocytopenia: improving quality of life and patient outcomes. Patient Relat Outcome Meas. 2018;9:369–384. doi:10.2147/PROM.S140932
   PubMed Web of Science ®Google Scholar
• McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83(2):150–154. doi:10.1002/ajh.20992
   PubMed Web of Science ®Google Scholar
• Flores A, Klaassen RJ, Buchanan GR, Neunert CE. Patterns and influences in health-related quality of life in children with immune thrombocytopenia: a study from the Dallas ITP Cohort. Pediatr Blood Cancer. 2017;64(8):e26405. doi:10.1002/pbc.26405
   Web of Science ®Google Scholar
• Klaassen RJ, Blanchette VS, Barnard D, et al. Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids’ ITP Tools. J Pediatr. 2007;150(5):510–515. doi:10.1016/j.jpeds.2007.01.037
   Web of Science ®Google Scholar
• Klaassen RJ, Mathias SD, Buchanan G, et al. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2012;58(3):395–398. doi:10.1002/pbc.23312
   Web of Science ®Google Scholar
• Mathias SD, Li X, Eisen M, Carpenter N, Crosby RD, Blanchette VS. A phase 3, randomized, double-blind, placebo-controlled study to determine the effect of romiplostim on health-related quality of life in children with primary immune thrombocytopenia and associated burden in their parents. Pediatr Blood Cancer. 2016;63(7):1232–1237. doi:10.1002/pbc.25984
   PubMed Web of Science ®Google Scholar
• Guo JC, Zheng Y, Chen HT, et al. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis. Oncotarget. 2018;9(6):7112–7125. doi:10.18632/oncotarget.23487
   Google Scholar
• Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–2536. doi:10.1002/ajh.23163
   PubMed Web of Science ®Google Scholar
• Gonzalez KJ, Zuluaga SO, DaRos CV, Rodriguez PP, Marti AC. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center. Ann Hematol. 2017;96(3):507–508. doi:10.1007/s00277-016-2896-3
   Web of Science ®Google Scholar
• Kuter DJ, Mathias SD, Rummel M, et al. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol. 2012;87(5):558–561.
   PubMed Web of Science ®Google Scholar
• George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009;144(3):409–415. doi:10.1111/j.1365-2141.2008.07464.x
   PubMed Web of Science ®Google Scholar
• Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes. 2007;5(1):11. doi:10.1186/1477-7525-5-11
   Google Scholar